Avidity Biosciences, Inc.
RNADrugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Q2 2027
Market Overview
Stock performance and key metrics
1 upcoming, 2 past
AOC 1001 (del-desiran)
DM1
AOC-1020
Facioscapulohumeral Muscular Dystrophy
AOC 1044
Duchenne Muscular Dystrophy
AOC 1001
DM1
AOC 1020
FSHD
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AOC 1001 (del-desiran) | Phase 3 | DM1 | - | - |
AOC-1020 | Phase 3 | Facioscapulohumeral Muscular Dystrophy | - | - |
AOC 1044 | Phase 3 | Duchenne Muscular Dystrophy | - | - |
AOC 1001 | Phase 2 | DM1 | - | - |
AOC 1020 | Phase 2 | FSHD | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Avidity Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Avidity Biosciences, Inc.'s (RNA) pipeline across Phase 3, Phase 2. Its lead program is AOC 1001 (del-desiran) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Avidity Biosciences, Inc.'s next FDA catalyst?→
Avidity Biosciences, Inc.'s (RNA) next tracked catalyst is a Phase 3 expected August 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RNA biotech catalysts?→
Add RNA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Avidity Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.